US drugmakers call on Russian government to stop discriminating against them

26 February 2016

Leading US drugmakers represented by US Pharmaceutical Research and Manufacturers of America (PhRMA) have called on the Russian government to stop discriminating against their business in the Russian pharmaceutical market, reports The Pharma Letter’s local correspondent.

According to a recent report, PhRMA members claim they face obstacles when trying to get into the Russian market, which is reflected in the introduction of restrictions for the participation of US drugmakers in government tenders for the purchases of drugs.

According to Victor Dmitriev, general director of the Association of Russian Pharmaceutical Manufacturers (ARPM), in recent years the share of domestic drugs in the Russian market has significantly increased, which is also due to the existing restrictions during public procurement of drugs in Russia, which banned purchases of foreign drugs which could be supplied by locally-produced analogues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK